|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A diffusible factor from arbuscular mycorrhizal fungi induces symbiosis-specific MtENOD11 expression in roots of Medicago truncatula显示文摘 | KOSUTA S CHABAUD M LOUGNON G | 2003 | Plant Physiology2003，131，： | 1 |
| 2 | Behavior of an anencephalic fetus studied by 4D sonography 显示文摘 | Andonotopo W Kurjak A Kosuta M I | 2005 | J Matern Fetal Neonatal Med2005，17，2： | 1 |
| 3 | A diffusible factor from arbuscular mycorrhizal fungi induces symbiosis-specific MtENODll expression in roots of Medicago truncatila 显示文摘 | Kosuta S Chabaud M Lougnon G | 2003 | Plant Physiology2003，131，95： | 1 |
| 4 | A diffusible factor from arbuscular mycorrhizal fungi induces symbiosis-specific MtENOD11 expression in roots of Medicago truncatula 显示文摘 | KOSUTA S CHABAUD M LOUGNON G | 2003 | Plant Physiology2003，131，： | 1 |
| 5 | A diffusible factor from arbuscular mycorrhizal fungi induces symbiosis- specific MtENODI 1 expression in roots of Medicago truncatila 显示文摘 | KOSUTA S CHABAUD M LOUGNON G | 2003 | Plant Physiology2003，131，： | 1 |
| 6 | Three - dimensional transvaginal ultrasound improves measurement of nuchal translu- cency 显示文摘 | Kurjak A Kupesic S Ivanci*c - Kosuta M | 1999 | J Perinat Med1999，27，2： | 1 |
| 7 | Cytokinin~ se cret agent of symbiosis显示文摘 | FRUGIER F KOSUTA S MURRAY J D | 2008 | Trends in Plant Science2008，13，3： | 1 |
| 8 | A diffusible factor from arbuseular mycorrhizal fungi induces symbiosis- specific MtENOD11 expression in roots of Medicago truncat-ula 显示文摘 | KOSUTA S CHABAUD M LOUGNON G | 2003 | Plant PhysioI2003，131，： | 1 |
| 9 | Comparison of postoperative hepatic function between laparoscopic and open cholecystectomy 显示文摘 | Hasukic S Kosuta D Muminhodzic K | 2005 | Med Princ Pract2005，14，： | 1 |
| 10 | A diffusi- ble factor from arbuscular mycorrhizal fungi induces symbiosis specific MtENODll expression in roots of medicago truncatula显示文摘 | Kosuta S Chabaud M Lougnon G | 2003 | Plant Physiol2003，131，3： | 1 |
| 11 | Drug-induced liver injury associated with noni (morinda citrifolia) juice and phenobarbital 显示文摘 | Mrzljak A Kosuta I Skrtie A | 2013 | Case Rep Gastroenterol2013，7，1： | 1 |
| 12 | Diffusible Factor from Arbuscular Mycorrhizal Fungi Induces Symbiosis-Specific MtENOD11 Expression in Roots of Medicago truncatula显示文摘 | SONJA KOSUTA MIREILLE CHABAUD GERALDINE LOUGNON | 2003 | Plant Physiol2003，131，： | 1 |
| 13 | Cytokinin: secret agent of synlbiosis 显示文摘 | Frugier F Kosuta S Mun'ay J D | 2008 | Trends in Plant Science2008，13，3： | 1 |
| 14 | Three-Dimensional Ultrasound and Power Doppler Improve the Diagnosis of Ovarian Lesions显示文摘 | Asim Kurjak Sanja Kupesic Tomislav Anic Dragutin Kosuta | 2000 | Gynecologic Oncology2000，，1： | 1 |
| 15 | Approach to persistent ascites after liver transplantation显示文摘Persistent ascites(PA)after liver transplantation(LT),commonly defined as ascites lasting more than 4 wk after LT,can be expected in up to 7%of patients.Despite being relatively rare,it is associated with worse clinical outcomes,including higher 1-year mortality.The cause of PA can be divided into vascular,hepatic,or extrahepatic.Vascular causes of PA include hepatic outflow and inflow obstructions,which are usually successfully treated.Regarding modifiable hepatic causes,recurrent hepatitis C and acute cellular rejection are the leading ones.Considering predictors for PA,the presence of ascites,refractory ascites,hepatorenal syndrome type 1,spontaneous bacterial peritonitis,hepatic encephalopathy,and prolonged ischemic time significantly influence the development of PA after LT.The initial approach to patients with PA should be to diagnose the treatable cause of PA.The stepwise approach in evaluating PA includes diagnostic paracentesis,ultrasound with Doppler,and an echocardiogram when a cardiac cause is suspected.Finally,a percutaneous or transjugular liver biopsy should be performed in cases where the diagnosis is unclear.PA of unknown cause should be treated with diuretics and paracentesis,while transjugular intrahepatic portosystemic shunt and splenic artery embolization are treatment methods in patients with refractory ascites after LT. | Ana Ostojic Igor Petrovic Hrvoje Silovski Iva Kosuta Maja Sremac Anna Mrzljak | 2022 | World Journal of Hepatology2022，14，9： | 0 |
| 16 | Immunology demystified: A guide for transplant hepatologists显示文摘Liver transplantation has become standard practice for treating end-stage liver disease.The success of the procedure relies on effective immunosuppressive medications to control the host's immune response.Despite the liver's inherent capacity to foster tolerance,the early post-transplant period is marked by significant immune reactivity.To ensure favorable outcomes,it is imperative to identify and manage various rejection types,encompassing T-cell-mediated,antibody-mediated,and chronic rejection.However,the approach to prescribing immunosuppressants relies heavily on clinical judgment rather than evidencebased criteria.Given that the majority of patients will require lifelong immunosuppression as the mechanisms underlying operational tolerance are still being investigated,healthcare providers must possess an understanding of immune responses,rejection mechanisms,and the pathways targeted by immunosuppressive drugs.This knowledge enables customization of treatments and improved patient care,even though a consensus on an optimal immunosuppressive regimen remains elusive. | Iva Kosuta Tomislav Kelava Ana Ostojic Vibor Sesa Anna Mrzljak Hrvoje Lalic | 2024 | World Journal of Transplantation2024，14，1： | 0 |
| 17 | Shifting perspectives in liver diseases after kidney transplantation显示文摘Liver diseases after kidney transplantation range from mild biochemical abnormalities to severe hepatitis or cirrhosis.The causes are diverse and mainly associated with hepatotropic viruses,drug toxicity and metabolic disorders.Over the past decade,the aetiology of liver disease in kidney recipients has changed significantly.These relates to the use of direct-acting antiviral agents against hepatitis C virus,the increasing availability of vaccination against hepatitis B and a better understanding of drug-induced hepatotoxicity.In addition,the emergence of the severe acute respiratory syndrome coronavirus 2 pandemic has brought new challenges to kidney recipients.This review aims to provide healthcare professionals with a comprehensive understanding of recent advances in the management of liver complications in kidney recipients and to enable them to make informed decisions regarding the risks and impact of liver disease in this population. | Iva Kosuta Ana Ostojic Ana Vujaklija Brajkovic Jaksa Babel Bojana Simunov Maja Sremac Anna Mrzljak | 2023 | World Journal of Hepatology2023，15，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员